Hubbry Logo
BronchitisBronchitisMain
Open search
Bronchitis
Community hub
Bronchitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Bronchitis
Bronchitis
Bronchitis
View on Wikipedia
from Wikipedia

Bronchitis
Figure A shows the location of the lungs and bronchial tubes. Figure B is an enlarged view of a normal bronchial tube. Figure C is an enlarged view of a bronchial tube with bronchitis.
Pronunciation
SpecialtyInfectious disease, pulmonology
SymptomsCoughing up mucus, wheezing, shortness of breath, chest discomfort[1]
TypesAcute, chronic[1]
FrequencyAcute: ~5% of people a year[2][3]
Chronic: ~5% of people[3]

Bronchitis is inflammation of the bronchi (large and medium-sized airways) in the lungs that causes coughing. Bronchitis usually begins as an infection in the nose, ears, throat, or sinuses. The infection then makes its way down to the bronchi. Symptoms include coughing up sputum, wheezing, shortness of breath, and chest pain. Bronchitis can be acute or chronic.[1]

Acute bronchitis usually has a cough that lasts around three weeks,[4] and is also known as a chest cold.[5] In more than 90% of cases, the cause is a viral infection.[4] These viruses may be spread through the air when people cough or by direct contact.[6] A small number of cases are caused by a bacterial infection such as Mycoplasma pneumoniae or Bordetella pertussis.[4] Risk factors include exposure to tobacco smoke, dust, and other air pollution.[6] Treatment of acute bronchitis typically involves rest, paracetamol (acetaminophen), and nonsteroidal anti-inflammatory drugs (NSAIDs) to help with the fever.[7][8]

Chronic bronchitis is defined as a productive cough – one that produces sputum – that lasts for three months or more per year for at least two years.[9][10] Many people with chronic bronchitis also have chronic obstructive pulmonary disease (COPD).[11] Tobacco smoking is the most common cause, with a number of other factors such as air pollution and genetics playing a smaller role.[12] Treatments include quitting smoking, vaccinations, rehabilitation, and often inhaled bronchodilators and steroids.[13] Some people may benefit from long-term oxygen therapy.[13]

Acute bronchitis is one of the more common diseases.[7][14] About 5% of adults and 6% of children have at least one episode a year.[2][15] Acute bronchitis is the most common type of bronchitis.[16] By contrast in the United States, in 2018, 9.3 million people were diagnosed with the less common chronic bronchitis.[17][18]

Acute bronchitis

[edit]
Main article: Acute bronchitis
Bronchitis

Acute bronchitis, also known as a chest cold, is a short-term inflammation of the bronchi of the lungs.[4][6] The most common symptom is a cough that may or may not produce sputum.[4][19] Other symptoms may include coughing up mucus, wheezing, shortness of breath, fever, and chest discomfort.[6] Fever when present is mild.[20] The infection may last a few to ten days.[6] The cough may persist for several weeks afterwards, with the total duration of symptoms usually around three weeks.[4][6] Symptoms may last for up to six weeks.[7]

Cause

[edit]

In more than 90% of cases, the cause is a viral infection.[4] These viruses may spread through the air when people cough or by direct contact.[6] Risk factors include exposure to tobacco smoke, dust, and other air pollutants.[6] A small number of cases are due to bacteria such as Mycoplasma pneumoniae or Bordetella pertussis.[4]

Diagnosis

[edit]

Diagnosis is typically based on a person's signs and symptoms.[20] The color of the sputum does not indicate if the infection is viral or bacterial.[4] Determining the underlying organism is usually not required.[4] Other causes of similar symptoms include asthma, pneumonia, bronchiolitis, bronchiectasis, and COPD.[2][4] A chest X-ray may be useful to detect pneumonia.[4]

Another common sign of bronchitis is a cough lasting ten days to three weeks. If the cough lasts longer than a month, it may become chronic bronchitis. In addition, a fever may be present. Acute bronchitis is normally caused by a viral infection. Typically, these infections are rhinovirus, adenovirus, parainfluenza, or influenza. No specific testing is normally needed to diagnose acute bronchitis.[20]

Treatment

[edit]

One form of prevention is to avoid smoking and other lung irritants.[21] Frequent hand washing may also be protective.[21] Treatment for acute bronchitis usually involves rest, paracetamol (acetaminophen), and NSAIDs to help with the fever.[7][8] Cough medicine has little support for its use, and is not recommended in children under the age of six.[4][22] There is tentative evidence that salbutamol may be useful in treating wheezing; however, it may result in nervousness and tremors.[4][23] Antibiotics should generally not be used.[19] An exception is when acute bronchitis is due to pertussis.[4] Tentative evidence supports honey and pelargonium to help with symptoms.[4] Getting plenty of rest and drinking enough fluids are often recommended as well.[24] Chinese medicinal herbs are of unclear effect.[25]

Epidemiology

[edit]

Acute bronchitis is one of the most common diseases[7][14] and the most common type of bronchitis.[5] About 5% of adults are affected, and about 6% of children have at least one episode yearly.[2][15] It occurs more often in the winter.[2] More than 10 million people in the U.S. visit a healthcare provider each year for this condition, with about 70% receiving antibiotics that are mostly unnecessary.[7] There are efforts to decrease the use of antibiotics in acute bronchitis.[14]

Chronic bronchitis

[edit]
See also: Chronic obstructive pulmonary disease

Chronic bronchitis is a lower respiratory tract disease,[26] defined by a productive cough that lasts for three months or more per year for at least two years.[1][10] The cough is sometimes referred to as a smoker's cough since it often results from smoking. When chronic bronchitis occurs together with decreased airflow it is known as chronic obstructive pulmonary disease (COPD).[27][26] Many people with chronic bronchitis have COPD; however, most people with COPD do not also have chronic bronchitis.[10][28] Estimates of the number of people with COPD who have chronic bronchitis are 7–40%.[29][30] Estimates of the number of people who smoke and have chronic bronchitis who also have COPD is 60%.[31]

The term "chronic bronchitis" was used in previous definitions of COPD but is no longer included in the definition.[10][32][33] The term is still used clinically.[34] While both chronic bronchitis and emphysema are often associated with COPD, neither is needed to make the diagnosis.[34] A Chinese consensus commented on symptomatic types of COPD that include chronic bronchitis with frequent exacerbations.[35]

Chronic bronchitis is marked by mucus hypersecretion and mucins.[9][36] The excess mucus is produced by an increased number of goblet cells, and enlarged submucosal glands in response to long-term irritation.[37] The mucous glands in the submucosa secrete more than the goblet cells.[38] Mucins thicken mucus, and their concentration has been found to be high in cases of chronic bronchitis, and also to correlate with the severity of the disease.[39] Excess mucus can narrow the airways, thereby limiting airflow and accelerating the decline in lung function, and result in COPD.[35][40] Excess mucus shows itself as a chronic productive cough and its severity and volume of sputum can fluctuate in periods of acute exacerbations.[35] In COPD, those with the chronic bronchitic phenotype with associated chronic excess mucus, experience a worse quality of life than those without.[35][41]

The increased secretions are initially cleared by coughing.[36] The cough is often worse soon after awakening, and the sputum produced may have a yellow or green color and may be streaked with specks of blood.[42] In the early stages, a cough can maintain mucus clearance. However, with continued excessive secretion mucus clearance is impaired, and when the airways become obstructed a cough becomes ineffective.[43] Effective mucociliary clearance depends on airway hydration, ciliary beating, and the rates of mucin secretion. Each of these factors is impaired in chronic bronchitis.[44] Chronic bronchitis can lead to a higher number of exacerbations and a faster decline in lung function.[40][45] The ICD-11 lists chronic bronchitis with emphysema (emphysematous bronchitis) as a "certain specified COPD".[46][47]

Cause

[edit]

Most cases of chronic bronchitis are caused by tobacco smoking.[48][49] Chronic bronchitis in young adults who smoke is associated with a greater chance of developing COPD.[50] There is an association between smoking cannabis and chronic bronchitis.[51][52] In addition, chronic inhalation of air pollution, or irritating fumes or dust from hazardous exposures in occupations such as coal mining, grain handling, textile manufacturing, livestock farming,[53] and metal moulding may also be a risk factor for the development of chronic bronchitis.[54][55][56] Bronchitis caused in this way is often referred to as industrial bronchitis, or occupational bronchitis.[57] Rarely genetic factors also play a role.[58]

Air quality can also affect the respiratory system with higher levels of nitrogen dioxide and sulfur dioxide contributing to bronchial symptoms. Sulfur dioxide can cause inflammation which can aggravate chronic bronchitis and make infections more likely.[59]

Air pollution in the workplace is the cause of several non-communicable diseases (NCDs) including chronic bronchitis.[60]

Treatment

[edit]

Decline in lung function in chronic bronchitis may be slowed by stopping smoking.[61][62] Chronic bronchitis may be treated with a number of medications and occasionally oxygen therapy.[1] Pulmonary rehabilitation may also be used.[1]

A distinction has been made between exacerbations (sudden worsenings) of chronic bronchitis, and otherwise stable chronic bronchitis. Stable chronic bronchitis can be defined as the normal definition of chronic bronchitis, plus the absence of an acute exacerbation in the previous four weeks.[45] A Cochrane review found that mucolytics in chronic bronchitis may slightly decrease the chance of developing an exacerbation.[63] The mucolytic guaifenesin is a safe and effective treatment for stable chronic bronchitis. This has an advantage in that it is available as an extended use tablet which lasts for twelve hours.[64] Erdosteine is a mucolytic recommended by NICE.[65] GOLD also supports the use of some mucolytics that are advised against when inhaled corticosteroids are being used, and singles out erdosteine as having good effects regardless of corticosteroid use. Erdosteine also has antioxidant properties. Erdosteine has been shown to significantly reduce the risk of exacerbations, shorten their duration, and hospital stays.[66] In those with the chronic bronchitic phenotype of COPD, the phosphodiesterase-4 inhibitor roflumilast may decrease significant exacerbations.[37]

Epidemiology

[edit]

Chronic bronchitis affects about 3.4–22% of the general population.[67] Individuals over 45 years of age, smokers, those that live or work in areas with high air pollution, and anybody with asthma all have a higher risk of developing chronic bronchitis.[68] This wide range is due to the different definitions of chronic bronchitis that can be diagnosed based on signs and symptoms or the clinical diagnosis of the disorder. Chronic bronchitis tends to affect men more often than women. While the primary risk factor for chronic bronchitis is smoking, there is still a 4–22% chance that non-smokers can get chronic bronchitis. This might suggest other risk factors such as the inhalation of fuels, dusts, fumes and genetic factor.[40] In the United States, in 2016, 8.6 million people were diagnosed with chronic bronchitis, and there were 518 reported deaths. Per 100,000 of population the death rate of chronic bronchitis was 0.2.[17]

History

[edit]

The condition of bronchitis has been recognised for many centuries, in several different cultures including the Ancient Greek, Chinese, and Indian, with the presence of excess phlegm and cough noted in recognition of the same condition. Early treatments of chronic bronchitis included garlic, cinnamon and ipecac, among others.[69] Modern treatments were developed during the second half of the 20th century.[70]

The British physician Charles Badham was the first person to describe the condition and name the acute form as acute bronchitis in his book Observations on the inflammatory affections of the mucous membrane of the bronchiæ, published in 1808. In this book, Badham distinguished three forms of bronchitis, including acute and chronic. A second, expanded edition of the book was published in 1814 with the title An essay on bronchitis.[69] Badham used the term catarrh to refer to the cardinal symptoms of chronic cough and mucus hypersecretion of chronic bronchitis, and described chronic bronchitis as a disabling disorder.[71]

In 1901 an article was published on the treatment of chronic bronchitis in the elderly. The symptoms described have remained unchanged. The cause was thought to be brought on by dampness, cold weather, and foggy conditions, and treatments were aimed towards various cough mixtures, respiratory stimulants, and tonics. It was noted that something other than the weather was thought to be at play.[72] Exacerbations of the condition were also described at this time. Another physician Harry Campbell was referred to who had written in the British Medical Journal a week before. Campbell had suggested that the cause of chronic bronchitis was due to toxic substances, and recommended pure air, simple food, and exercise to remove them from the body.[72]

A joint research programme was undertaken in Chicago and London from 1951 to 1953 in which the clinical features of one thousand cases of chronic bronchitis were detailed. The findings were published in the Lancet in 1953.[73] It was stated that since its introduction by Badham, chronic bronchitis had become an increasingly popular diagnosis. The study had looked at various associations such as the weather, conditions at home, and at work, age of onset, childhood illnesses, smoking habits, and breathlessness. It was concluded that chronic bronchitis invariably led to emphysema, particularly when the bronchitis had persisted for a long time.[73]

In 1957 it was noted that at the time there were many investigations being carried out into chronic bronchitis and emphysema in general, and among industrial workers exposed to dust.[74] Excerpts were published dating from 1864 in which Charles Parsons had noted the occurring consequence of the development of emphysema from bronchitis. This was seen to be not always applicable. His findings were in association with his studies on chronic bronchitis among pottery workers.[74]

A CIBA (now Novartis) meeting in 1959, and a meeting of the American Thoracic Society in 1962, defined chronic bronchitis as a component of COPD, in the terms that have not changed.[71][75]

Eosinophilic bronchitis

[edit]
Main article: Eosinophilic bronchitis

Eosinophilic bronchitis is a chronic dry cough, defined by the presence of an increased number of a type of white blood cell known as eosinophils. It has a normal finding on X-ray and has no airflow limitation.[76]

Protracted bacterial bronchitis

[edit]

Protracted bacterial bronchitis in children, is defined as a chronic productive cough with a positive bronchoalveolar lavage that resolves with antibiotics.[77][78] Protracted bacterial bronchitis is usually caused by Streptococcus pneumoniae, non-typable Haemophilus influenzae, or Moraxella catarrhalis.[78] Protracted bacterial bronchitis (lasting more than 4 weeks) in children may be helped by antibiotics.[79]

Plastic bronchitis

[edit]
Plastic bronchitis bronchial casts[80]

Plastic bronchitis is a rarely found condition in which thickened secretions plug the bronchi.[81][82] The plugs are rubbery or plastic-feeling (thus the name). The light-colored plugs take the branching shape of the bronchi that they fill, and are known as bronchial casts.[81] When these casts are coughed up, they are firmer in texture from typical phlegm or the short, softer mucus plugs seen in some people with asthma.[81] However, some people with asthma have larger, firmer, and more complex plugs. These differ from the casts seen in people whose plastic bronchitis is associated with congenital heart disease or lymphatic vessel abnormalities mainly because eosinophils and Charcot–Leyden crystals are present in the asthma-associated casts but not in the others.[81]

Casts obstruct the airflow, and can result in the overinflation of the opposite lung. Plastic bronchitis usually occurs in children. Some cases may result from abnormalities in the lymphatic vessels. Advanced cases may show imaging similarities to bronchiectasis.[82]

Eosinophilic plastic bronchitis

[edit]

Eosinophilic plastic bronchitis is a subtype of plastic bronchitis that is more often found in children. Symptoms may include a cough, and wheezing, and imaging may reveal a lung that is completely collapsed.[83] Depending on the size of the casts, and the location the condition may present with mild symptoms, or prove fatal.[83]

Aspergillus bronchitis

[edit]

Aspergillus bronchitis is a type of aspergillosis, a fungal infection caused by Aspergillus a common mold that affects the bronchi. Unlike other types of pulmonary aspergillosis, it can affect individuals who are not immunocompromised.[84][85] In immunocompetent individuals, Aspergillus bronchitis may manifest as persistent respiratory infections or symptoms that do not respond to antibiotics, but may improve with antifungals.[86]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Bronchitis

View on Grokipedia
from Grokipedia
Bronchitis is an inflammation of the lining of the bronchial tubes, the airways that carry air to and from the lungs, leading to thickened production and ing. It is classified into two main types: , a short-term condition that typically resolves within a few weeks and is often triggered by viral infections, and chronic bronchitis, a long-term disorder defined by a productive lasting at least three months in two consecutive years, commonly associated with (COPD). Acute bronchitis, sometimes referred to as a chest cold, is most frequently caused by viruses such as those responsible for the , , respiratory syncytial virus (RSV), or , and it can spread through respiratory droplets or contact with contaminated surfaces. Bacterial infections account for a small percentage of cases, while chronic bronchitis arises primarily from prolonged exposure to irritants, with cigarette smoking as the predominant cause, alongside environmental factors like , dust, and chemical fumes. Risk factors for both forms include weakened immune systems, occupational exposure to lung irritants, and . Symptoms of bronchitis commonly include a persistent , which may produce clear, white, yellow, or green , along with chest discomfort, fatigue, and mild . In , additional signs such as a low-grade fever below 100.4°F (38°C), , runny nose, and body aches often accompany the cough, with symptoms generally lasting less than three weeks. Chronic bronchitis features a more severe and ongoing with production, wheezing, frequent respiratory infections, and progressive breathing difficulties that can significantly impair daily activities. While usually improves with rest, hydration, and over-the-counter remedies without antibiotics, chronic bronchitis requires long-term management, including , bronchodilators, and to prevent complications like or . Prevention strategies emphasize avoiding tobacco smoke, getting vaccinated against and pneumococcal disease, practicing good hand , and minimizing exposure to airborne irritants.

Overview

Definition

Bronchitis is an of the lining of the bronchial tubes, the major airways that conduct air from the trachea into the lungs. This causes the airways to narrow and triggers excess production, impairing normal . The bronchial tree forms a key component of the lower , branching from the trachea into progressively smaller bronchi and bronchioles that deliver air to the alveoli for . These structures, lined with ciliated and -producing cells, protect the lungs by trapping and expelling particles while maintaining humidified . In distinction to , which involves of the and alveoli leading to impaired at the alveolar level, bronchitis is confined to the bronchi without parenchymal involvement. Similarly, affects the trachea, the cartilaginous tube connecting the to the bronchi, rather than the distal bronchial passages. Bronchitis occurs in both acute and chronic forms, with the former typically resolving within weeks and the latter persisting for months or years.

Classification

Bronchitis is primarily classified into two main forms based on duration and clinical course: acute and chronic. is characterized by a sudden onset of bronchial , typically lasting less than three weeks, and is most often triggered by viral infections such as those causing the or . In contrast, chronic bronchitis involves persistent of the bronchi, defined by a productive lasting at least three months per year for two consecutive years, and is frequently associated with long-term irritants like cigarette .

Signs and Symptoms

General Presentation

Bronchitis is characterized by of the bronchial tubes, leading to a range of respiratory symptoms that primarily affect the airways. The hallmark symptom is a , which may be dry or productive, often persisting as the most prominent feature across presentations. This is frequently accompanied by chest discomfort, such as soreness or a feeling of tightness in the chest, which arises from the of the inflamed airways. Additional primary symptoms include , resulting from the body's response to and increased respiratory effort, and a mild fever, typically low-grade and sometimes associated with . Associated features often involve wheezing, a high-pitched whistling sound during due to narrowed airways, and , particularly during , as the inflamed bronchioles impede normal airflow. production is common in productive cases, with that can appear clear, white, yellowish-gray, or green in color, reflecting the presence of inflammatory cells or possible , though it is usually not streaked with blood unless complications arise. The consistency of the varies but is often thick and sticky, contributing to the urge to . In uncomplicated cases, symptoms generally follow a progressive course where initial acute leads to peak discomfort within the first few days, followed by gradual improvement as the airways heal. Most manifestations, including fever and chest discomfort, resolve within one to two weeks, though the may linger for several weeks due to ongoing bronchial sensitivity. This progression underscores the self-limiting nature of the condition in the absence of underlying issues. Dizziness is not a typical symptom of bronchitis. However, it can occur in severe cases or due to complications. The primary cause is often hypoxemia (low blood oxygen levels) resulting from impaired lung function, which reduces oxygen supply to the brain. Other contributing factors may include intense coughing leading to lightheadedness, dehydration, or complications such as pneumonia or respiratory failure. Individuals experiencing dizziness alongside bronchitis symptoms should seek urgent medical care, as this may indicate a serious condition requiring prompt evaluation.

Differences Between Acute and Chronic Forms

Acute bronchitis typically presents with a sudden onset of symptoms following a viral upper respiratory , manifesting as a persistent that lasts 1 to 3 weeks and is often self-limiting with minimal long-term respiratory effects. In contrast, chronic bronchitis involves a gradual development of persistent symptoms, defined clinically as a productive lasting at least 3 months per year for 2 consecutive years, accompanied by daily production and recurrent exacerbations that contribute to progressive airway obstruction. The symptom evolution in acute cases generally resolves fully without residual damage, with the and associated production subsiding within 10 to 20 days in most instances, though mild or wheezing may linger briefly. Chronic bronchitis, however, features a more severe and unrelenting progression, leading to irreversible airway and remodeling, frequent infections, and escalating that worsens over time, often resulting in significant limitations in daily activities.
AspectAcute BronchitisChronic Bronchitis
OnsetSudden, often post-viralGradual, persistent over years
Duration1–3 weeks, self-resolving≥3 months/year for ≥2 years, with ongoing recurrences
Key SymptomsTransient (dry or productive), mild fever, chest discomfortDaily productive with , wheezing, , recurrent exacerbations
ProgressionFull resolution, no lasting effectsIrreversible damage, increasing severity, recurrent infections
SeverityGenerally mild, benign courseModerate to severe, linked to progressive impairment
This distinction underscores the transient nature of acute episodes versus the chronic, debilitating trajectory of the latter form.

Pathophysiology

Mechanisms in Acute Bronchitis

Acute bronchitis arises from an acute inflammatory response in the bronchial mucosa, primarily triggered by viral infections such as or , though irritants like pollutants or allergens can also initiate the process. This inflammation involves hyperemia and increased , leading to bronchial that thickens the mucosal lining and promotes epithelial cell , thereby narrowing the airways and increasing resistance to airflow. Concurrently, the inflammatory cascade stimulates goblet cell and submucosal gland , resulting in mucus hypersecretion that further obstructs the bronchi and impairs . Central to this process are immune cells, particularly neutrophils, which are recruited to the site of through such as RANTES and MCP-1 released by infected epithelial cells. These neutrophils, along with pro-inflammatory like TNF-alpha, IL-6, and IFN-alpha, exacerbate airway narrowing by releasing and proteases such as , which damage local tissues and amplify production while inducing . T lymphocytes also contribute to the acute phase by sustaining release, though their role is more prominent in the initial immune activation rather than prolonged inflammation. The condition is typically self-limiting, with resolution occurring through the natural repair of the bronchial epithelium and clearance of inflammatory debris and pathogens, often within 1 to 3 weeks. Epithelial regeneration restores the mucosal barrier, while enhanced mucociliary function facilitates the expulsion of excess and cellular remnants, returning airway patency to normal without residual structural damage.

Mechanisms in Chronic Bronchitis

Chronic bronchitis arises from repeated injury to the bronchial , primarily due to prolonged exposure to irritants such as cigarette smoke, which initiates a cascade of pathological changes in the airways. This ongoing insult leads to hyperplasia, where submucosal glands hypertrophy and the number of mucus-producing goblet cells increases, resulting in excessive mucus secretion and airway narrowing. Concurrently, occurs as the normal ciliated columnar transforms into , impairing and exacerbating mucus retention. further contributes by causing peribronchial scarring and thickening of the bronchial walls, often quantified by an elevated greater than 0.4, which perpetuates structural remodeling. Central to these changes is chronic , driven by persistent recruitment of s and macrophages, which release pro-inflammatory cytokines such as TNF-α and CXCL8, sustaining epithelial damage and hypersecretion. plays a pivotal role, with (ROS) from smoke and activated neutrophils causing and activating (EGFR), thereby promoting differentiation and of structural cells. This oxidative burden also inactivates antiproteases like α1-antitrypsin, tipping the protease-antiprotease balance toward excess proteases such as neutrophil elastase and matrix metalloproteinases (MMPs), which degrade components including and . The resulting imbalance fosters further through chemotactic peptide generation and contributes to airflow obstruction by eroding airway integrity and inducing peribronchial . These mechanisms distinguish chronic bronchitis as a key within (COPD), characterized by lower airway remodeling that includes goblet cell metaplasia, basal cell hyperplasia, and increased airway wall thickness observable on computed tomography. In this context, chronic bronchitis drives progressive airflow limitation through mucous plugging and structural alterations in small airways, with studies showing greater bronchial wall area percentages in affected patients compared to non-bronchitic COPD phenotypes. The interplay of inflammation, , and proteolytic activity not only amplifies remodeling but also correlates inversely with forced expiratory volume in one second (FEV1), underscoring the irreversible nature of these changes.

Acute Bronchitis

Causes

Acute bronchitis is most commonly caused by viral infections, accounting for approximately 90-95% of cases in otherwise healthy adults. Common viruses include those responsible for the (rhinoviruses), , (RSV), and coronaviruses such as (). These infections spread through respiratory droplets from coughing or sneezing, or by touching contaminated surfaces and then the face. Bacterial causes are less common, representing about 5-10% of cases, typically involving pathogens like or in specific populations. Unlike chronic bronchitis, acute bronchitis is not primarily linked to long-term irritant exposure but rather to acute respiratory infections, though irritants like cigarette smoke can exacerbate symptoms.

Diagnosis

Diagnosis of acute bronchitis is primarily clinical, based on a patient's and , without the need for routine laboratory tests or imaging in uncomplicated cases. Key features include a lasting less than three weeks, often productive of clear or mucopurulent , accompanied by symptoms such as chest discomfort, low-grade fever (below 100.4°F or 38°C), , runny nose, or mild . The absence of signs suggesting (e.g., high fever, focal findings) or other conditions like or supports the diagnosis. is not typically required, unlike in chronic bronchitis or COPD, but may be considered in patients with risk factors such as or recurrent episodes to assess for underlying disease. Chest X-rays are reserved for cases with red flags like bloody , severe dyspnea, or symptoms persisting beyond three weeks to rule out or other pathologies. Guidelines from organizations like the American Academy of Family Physicians (AAFP) emphasize avoiding unnecessary antibiotics based on clinical presentation alone.

Treatment

Treatment for acute bronchitis focuses on symptom relief and supportive care, as the condition is usually self-limited and resolves within 1-3 weeks without specific antiviral or antibiotic therapy in most cases. Antibiotics are not recommended for viral causes, which predominate, and their use can lead to resistance and side effects; they are only indicated if a bacterial infection is confirmed, such as in pertussis-suspected cases. Over-the-counter medications include cough suppressants (e.g., dextromethorphan) for dry coughs, expectorants (e.g., guaifenesin) for productive coughs, and pain relievers (e.g., acetaminophen or ibuprofen) for fever and discomfort. Home remedies such as rest, hydration, humidified air, honey (for adults and children over 1 year), and throat lozenges can alleviate symptoms. In patients with wheezing, short-acting bronchodilators like albuterol may provide relief, particularly those with underlying reactive airway disease. Hospitalization is rare but may be needed for severe cases in high-risk groups like infants or the elderly.

Prevention

Prevention of acute bronchitis centers on reducing exposure to respiratory viruses and minimizing airway irritation. Key strategies include annual influenza , which can prevent flu-related cases, and pneumococcal vaccination for at-risk individuals to avoid secondary bacterial complications. Good hand hygiene—washing with soap and water or using alcohol-based sanitizer—along with avoiding close contact with sick people and covering coughs/sneezes, limits viral spread. Avoiding cigarette smoke and is crucial, as smoking impairs defenses and prolongs recovery. For occupational exposures, using protective equipment in environments with or chemicals can help. Unlike chronic bronchitis prevention, which emphasizes long-term irritant avoidance, acute measures focus on infection control, with no specific prophylaxis like masks recommended routinely outside outbreaks.

Epidemiology

Acute bronchitis is one of the most common acute respiratory illnesses, affecting an estimated 5% of adults annually in the United States, ranking among the top 10 outpatient diagnoses. Globally, it contributes to a significant burden of acute respiratory infections, with incidence peaking during winter months in temperate climates due to seasonal viruses like and RSV. As of 2024-2025 data, it impacts all age groups but is more frequent in children under 5 and adults over 65, with higher rates in smokers and those with weakened immunity. In settings, it accounts for up to 10% of visits, though exact global figures vary; the notes rising trends in acute respiratory infections in the during winter 2025. Unlike chronic bronchitis, which affects 3-22% of adults long-term as part of COPD, acute cases are transient and resolve without sequelae in most healthy individuals.

Chronic Bronchitis

Causes

Chronic bronchitis is primarily caused by long-term exposure to irritants that damage the airways, with cigarette accounting for 80-90% of cases in developed countries. This exposure leads to repeated and hypersecretion in the bronchial tubes, contributing to the persistent characteristic of the condition. Other environmental factors play a significant role, including from sources such as vehicle emissions and industrial fumes, which exacerbate airway irritation in susceptible individuals. Occupational exposures to dust, chemicals, and vapors—common in industries like , , and —also increase risk by causing chronic independent of or in addition to . Genetic predispositions contribute to susceptibility, particularly , a hereditary condition that impairs the body's ability to protect lung tissue from damage, elevating the risk of developing chronic bronchitis even with moderate irritant exposure. This genetic factor is the only well-established inherited risk for the disease. Chronic bronchitis represents a clinical subtype of (COPD), distinguished by its emphasis on productive cough and mucus production rather than predominant emphysema-like changes. In contrast to , which is typically triggered by transient infections, chronic forms arise from sustained irritant exposure.

Diagnosis

The diagnosis of chronic bronchitis, a clinical of (COPD), relies on both clinical history and objective to confirm persistent airflow limitation. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, a key clinical criterion is a productive with production lasting at least 3 months per year for 2 consecutive years, often accompanied by a history of risk factors such as or environmental exposures. Objective confirmation requires , which demonstrates airflow obstruction characterized by a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced (FVC) ratio of less than 0.70. This test distinguishes chronic bronchitis from normal lung function and is essential for establishing chronicity, unlike , which is typically diagnosed based on clinical history alone without routine spirometry. Chest X-ray may reveal nonspecific signs such as or increased bronchovascular markings, helping to exclude alternative causes like or . In select cases, (CT) of the chest is used to exclude significant , which presents with parenchymal destruction and low-attenuation areas, allowing phenotyping of COPD as predominantly chronic bronchitis. Differential diagnosis involves ruling out conditions that mimic chronic bronchitis symptoms, such as or , through targeted assessments. Bronchodilator reversibility testing during , defined as an increase in FEV1 of at least 12% and 200 mL, helps differentiate , where reversibility is more pronounced, from the largely irreversible obstruction in chronic bronchitis. For suspected , additional evaluation with biomarkers like B-type natriuretic peptide (BNP) levels or is considered alongside to identify cardiac contributions to dyspnea, as airflow limitation alone does not exclude .

Treatment

The cornerstone of treatment for chronic bronchitis is , which significantly reduces production, , airflow limitation, and disease progression. Pharmacological support for quitting includes , bupropion, , and counseling, which can increase quit rates by up to 25%. Long-term pharmacotherapy focuses on bronchodilators as first-line agents to relieve symptoms, reduce exacerbations, and improve exercise capacity. Long-acting beta-agonists (LABA), such as indacaterol, and long-acting muscarinic antagonists (), such as tiotropium or aclidinium, decrease gas trapping and sputum production, with combination LABA/ therapy providing greater improvements in function than monotherapy. Ensifentrine, an inhaled dual and 4 inhibitor approved in 2024, offers additional bronchodilation and effects as maintenance therapy, improving function and reducing exacerbations when added to existing regimens. For patients with frequent exacerbations, particularly those with blood eosinophil counts ≥300 cells/μL, inhaled corticosteroids (ICS) are added to LABA/ regimens to further control and exacerbation risk, though they carry risks of and . Biologics such as (for moderate-to-severe COPD with ) and (approved in 2025 for eosinophilic COPD) are recommended as add-on therapies for patients with persistent exacerbations and elevated , targeting to reduce event rates. Mucus clearance strategies include mucolytics like N-acetylcysteine, which can reduce frequency by approximately 0.36 per year and improve health status in patients with chronic bronchitis not on ICS. , typically lasting 6-8 weeks, enhances exercise capacity, reduces dyspnea, and improves across all severities of chronic bronchitis, with benefits extending to post-exacerbation recovery. For advanced cases, long-term is recommended in patients with severe (PaO₂ ≤55 mmHg or SaO₂ ≤88%), improving survival and reducing complications like , with reassessment after 60-90 days. In severe chronic bronchitis associated with upper-lobe and hyperinflation, lung volume reduction surgery (LVRS) may improve FEV₁, exercise tolerance, and in select patients, though it carries higher mortality risk if FEV₁ ≤20% predicted.

Prevention

Preventing chronic bronchitis primarily involves addressing modifiable risk factors, with being the cornerstone of primary prevention strategies. smoking accounts for up to 75% of chronic bronchitis cases, making avoidance in nonsmokers and cessation in current smokers the most effective intervention to halt disease progression and reduce symptom severity. Public health programs, such as those promoted by the (WHO) and the Centers for Disease Control and Prevention (CDC), emphasize comprehensive support, including counseling, nicotine replacement therapies, and pharmacological aids like , which have demonstrated success in long-term quit rates among high-risk populations. Additionally, avoiding exposure is crucial, as it contributes to airway inflammation and disease development in nonsmokers. Workplace and environmental protections form another key aspect of primary prevention by minimizing exposure to respiratory irritants. Occupational hazards such as dust, chemical fumes, and air pollutants are significant risk factors for chronic bronchitis, particularly in industries like mining and manufacturing; implementing engineering controls, personal protective equipment like respirators, and regulatory standards can substantially lower incidence rates. The WHO advocates for clean household energy solutions to reduce indoor air pollution from biomass fuels, which exacerbates chronic lung conditions in vulnerable communities. Secondary prevention focuses on mitigating exacerbations and enabling early detection in at-risk groups. Annual vaccination and pneumococcal are recommended by the CDC for individuals with chronic bronchitis or other (COPD) to prevent severe respiratory infections that can worsen symptoms and lead to hospitalizations. Early screening through testing is advised for smokers over age 40 or those with prolonged , allowing for timely interventions to preserve lung function. Lifestyle modifications, including regular physical activity such as programs and a diet rich in fruits, vegetables, and whole grains, support improved lung capacity and reduced inflammation; these approaches have been shown to enhance and slow disease advancement. For measures targeting acute infections, refer to the prevention section under .

Epidemiology

Chronic bronchitis, a key clinical of (COPD), affects an estimated 3% to 22% of the global adult population, with prevalence rates among COPD patients ranging from 27% to 35% based on the classic definition of productive cough for at least three months in two consecutive years. As a component of COPD, which impacts approximately 10.3% of adults worldwide, chronic bronchitis contributes to heightened risks of exacerbations, hospitalizations, and mortality within the broader spectrum of obstructive lung diseases. In the United States alone, nearly 10 million adults are affected, predominantly those aged 44 to 65 years. Prevalence is substantially higher among smokers, where 10% to 20% of individuals develop clinically significant chronic bronchitis as part of COPD, compared to much lower rates in never-smokers (4% to 22% attributable to non-tobacco exposures like ). Demographically, the condition is more common in males, adults over 40 years (peaking beyond age 60), and populations in low- and middle-income countries, where household air pollution from biomass fuels and occupational exposures exacerbate risks, particularly in rural areas. Regional variations are evident, with higher rates reported in (7.8% to 19.7%) and low-socioeconomic settings influenced by environmental factors. Epidemiological trends show a decline in chronic bronchitis prevalence in high-income countries, driven by reduced rates and interventions, as observed in nations like and where age-standardized rates have decreased alongside tobacco cessation efforts. Conversely, in developing regions, prevalence is rising due to increasing use, urbanization-related , and persistent biomass fuel exposure, with global COPD cases (including chronic bronchitis phenotypes) projected to grow by 23% to nearly 600 million by 2050, disproportionately affecting low- and middle-income areas.

Other Variants

Eosinophilic Bronchitis

is a type of characterized by in the airways without the presence of asthma-like features such as airflow obstruction or . It typically presents as a persistent dry or minimally productive cough lasting more than eight weeks, affecting approximately 5% to 30% of patients evaluated for unexplained . Unlike typical bronchitis, it involves a specific inflammatory pattern driven by , which are that accumulate in the , often exceeding 3% of total cells. This condition shows a female predominance and typically occurs in middle-aged adults, with symptoms frequently accompanied by or production in a majority of cases. The hallmark characteristics include a cough-dominant without variable airflow limitation, distinguishing it from , and normal function tests that rule out obstructive . analysis reveals elevated , averaging around 25-30% in affected individuals, reflecting allergic-type localized primarily to the lower airways. There is no association with or history in most cases, and the may involve increased activity in the bronchial , leading to via neural mechanisms rather than smooth muscle constriction. Some patients may experience progression to or , though the condition often follows a relapsing course. Causes of eosinophilic bronchitis are not fully elucidated but are commonly linked to exposure to allergens or occupational sensitizers, such as resin hardeners, fumes, , or dust, which trigger recruitment to the airways. Environmental inhalants may also play a role, promoting the release of inflammatory mediators like interleukin-13 without inducing the hyperresponsiveness seen in . The condition responds effectively to corticosteroids, which reduce counts and alleviate symptoms, supporting an inflammatory basis amenable to therapy. Diagnosis relies on induced sputum analysis as the gold standard, confirming greater than 3% after excluding other etiologies through clinical history, chest , and . shows normal values, with forced exceeding 80% predicted and above 75%, indicating no obstruction. Bronchial hyperresponsiveness is absent, typically with a PC20 value greater than 8 mg/mL, differentiating it from where variability in peak flow or hyperresponsiveness is present. Elevated exhaled levels can serve as a supportive for airway .

Protracted Bacterial Bronchitis

Protracted bacterial bronchitis (PBB) is defined as a chronic wet or productive persisting for more than 4 weeks in the absence of alternative causes, such as or structural abnormalities, and typically resolves with a course of appropriate antibiotics. This condition arises from bacterial colonization and infection of the lower airways, leading to and purulent secretions observable via . The hallmark feature is the wet , which may worsen with activity or postural changes and is often accompanied by minimal systemic symptoms like low-grade fever or . The primary bacterial pathogens involved in PBB include nontypeable Haemophilus influenzae (prevalent in 47–81% of cases), Streptococcus pneumoniae (24–39%), and Moraxella catarrhalis (19–43%), with cultures from bronchoalveolar lavage confirming endobronchial infection. These organisms colonize the bronchial mucosa, promoting neutrophilic inflammation and persistent symptoms. PBB is distinguished from acute bronchitis by its prolonged duration and from eosinophilic bronchitis by its infectious rather than allergic etiology, where the latter involves eosinophil-predominant inflammation without bacterial involvement. PBB predominantly affects children under 6 years of age, with a mean age of 1.8–4.8 years, and is more common in males. It occurs in 11–41% of children referred to pediatric pulmonologists for and is particularly prevalent among those with recurrent respiratory infections or underlying conditions like , where poor control exacerbates risk. Immunocompromised children or those with may also be susceptible, as these factors impair airway clearance and bacterial eradication. Treatment centers on prolonged to eradicate , with a standard regimen of 2 weeks of high-dose amoxicillin-clavulanate (or alternatives like cephalosporins or based on local resistance patterns), extendable to 4 weeks if initial response is incomplete. A positive response to this therapy supports the PBB , and bronchoscopy-guided cultures can tailor antibiotics for resistant cases, such as . Prevention strategies emphasize routine vaccinations against S. pneumoniae and to reduce overall bacterial load, alongside avoiding environmental tobacco smoke exposure and promoting good and to bolster respiratory . Early intervention is crucial to prevent progression to in recurrent cases (more than three episodes per year).

Plastic Bronchitis

Plastic bronchitis is a rare and potentially life-threatening respiratory condition characterized by the formation of large, rubbery, branching casts within the bronchi, which can obstruct airways and lead to or . These casts, often expectorated by patients, mimic the shape of the bronchial tree and consist of , , and inflammatory cells, distinguishing the disorder from typical plugging in other airway diseases. The condition is classified into two main types: Type I (inflammatory) casts with cellular infiltrates including and lymphocytes, and Type II (acellular) casts primarily composed of with minimal cellularity. The of plastic bronchitis is multifactorial and can be broadly categorized as secondary to underlying conditions or idiopathic. Common causes include post-surgical complications, particularly following the for congenital heart defects, where lymphatic abnormalities lead to endobronchial seepage of lymph fluid into the airways, with an incidence of approximately 1-4% among affected patients. Other triggers encompass infections (viral, bacterial, or fungal, such as occasional involvement) and inflammatory states, while idiopathic cases lack identifiable precipitants. The subtype, a form of Type I plastic bronchitis, is particularly associated with allergic or conditions, including and , where eosinophil-driven inflammation promotes cast formation; up to 67% of reported cases in children exhibit atopy. Management of plastic bronchitis focuses on immediate airway clearance and addressing underlying causes to prevent recurrence. remains the cornerstone for and treatment, enabling direct visualization and removal of casts via techniques such as extraction or cryoextraction, which is essential to relieve obstruction. therapies, including systemic or inhaled corticosteroids, are commonly employed to reduce airway , particularly in the subtype, with adjunctive measures like bronchodilators, mucolytics (e.g., ), and targeted lymphatic interventions (e.g., in post-Fontan cases) used based on . In refractory cases, novel biologics such as have shown promise for eosinophil-mediated disease by inhibiting IL-4 and IL-13 pathways.

Aspergillus Bronchitis

Aspergillus bronchitis is a chronic primarily caused by that affects the damaged airways, leading to necrotizing characterized by superficial invasion of the bronchial mucosa and formation of pseudomembranes or ulcers. This condition represents a form of lower airway , distinct from parenchymal involvement, and is marked by persistent and without significant pulmonary infiltrates. It typically manifests as a protracted illness lasting over four weeks, with hyphal elements penetrating the tracheobronchial tree and causing tissue . Individuals at highest risk for bronchitis are those with underlying immunocompromising conditions, including , solid organ transplants such as lung or heart-lung transplantation, and prolonged corticosteroid use. Other predisposing factors encompass structural lung damage from , continuous antibiotic therapy that disrupts normal flora, and states of or hematologic malignancies. Common symptoms include chronic productive cough with tenacious sputum, dyspnea, difficult airway clearance, and notably , which can range from mild streaking to life-threatening bleeding due to vascular invasion. In transplant recipients, symptoms may be subtler, such as fever or asymptomatic progression, but airway obstruction can lead to if untreated. Diagnosis relies on a combination of clinical , , and microbiological confirmation, with being essential to visualize pseudomembranous plaques or ulcerative lesions and obtain samples for fungal cultures. Positive or cultures for A. fumigatus, along with supportive tests like serum Aspergillus-specific IgG antibodies or galactomannan detection, confirm active , particularly when total IgE levels remain below 200 kU/L to differentiate from allergic forms. Computed may reveal bronchial wall thickening or dilation without parenchymal opacities, aiding in ruling out invasive pulmonary . Treatment centers on systemic antifungal therapy, with as the first-line agent due to its efficacy against species and favorable for airway penetration, often administered for at least 6-12 weeks depending on response. Adjunctive measures include bronchoscopic to remove pseudomembranes and alleviate obstruction, while may be used in cases of voriconazole intolerance or severe infection. In high-risk patients, such as those with or post-transplant status, combination therapy or surgical intervention for complications like massive is considered, with overall prognosis improving through early intervention to prevent progression to disseminated disease.

Complications and Differential Diagnosis

Potential Complications

While acute bronchitis is typically self-limiting and resolves without long-term issues, it can rarely lead to secondary bacterial infections or , particularly in individuals with underlying conditions such as weakened immune systems, , or chronic lung diseases. In such cases, the risk arises from bacterial following the initial viral , potentially prolonging symptoms or requiring intervention. Chronic bronchitis, as a component of (COPD), carries more significant risks, including frequent exacerbations triggered by infections or irritants, which can lead to in severe instances. Another potential is cor pulmonale, where chronic and strain the right side of the heart, resulting in and eventual . Severe hypoxemia in advanced cases, particularly in chronic bronchitis, or complications such as pneumonia can lead to symptoms such as dizziness due to reduced cerebral oxygenation, reinforcing the need for prompt medical intervention if such symptoms arise. Over the long term, chronic bronchitis is associated with accelerated decline in lung function, measured by reduced forced expiratory volume in one second (FEV1), and heightened cardiovascular risks, including and , due to and . These effects contribute to progressive respiratory impairment and reduced , with studies showing an approximately 2-3 times faster annual FEV1 decline (47-80 mL/year versus 20-30 mL/year in non-smokers). Early intervention is crucial to mitigate progression to advanced COPD or ; strategies include , which can halt further lung function decline, and vaccinations against and pneumococcus to reduce frequency. Inhaled bronchodilators and corticosteroids may also be employed to manage inflammation and prevent irreversible airway remodeling.

Distinguishing from Similar Conditions

Distinguishing bronchitis from similar respiratory conditions is essential for appropriate , as overlapping symptoms like and production can mimic other diseases. Acute typically presents with a self-limited following a viral upper respiratory infection, lacking focal findings on physical exam or , whereas often involves more severe systemic symptoms and radiographic evidence of consolidation. For instance, chest X-rays in may reveal infiltrates or lobar involvement, which are absent in uncomplicated , aiding differentiation through when clinical features overlap. Chronic bronchitis, characterized by persistent productive cough for at least three months over two consecutive years, must be differentiated from , particularly in patients with wheezing or dyspnea. Asthma features reversible airflow obstruction on , with improvements following administration, in contrast to the fixed or minimally reversible obstruction seen in chronic bronchitis as part of (COPD). A history of , episodic symptoms, or significant response points toward asthma, while daily production without such reversibility supports chronic bronchitis. Cough from (GERD) or postnasal drip syndrome can resemble bronchitis, especially in chronic cases, but responds differently to targeted therapies. GERD-related cough often worsens postprandially or nocturnally and may improve with proton pump inhibitors or acid suppression, distinguishing it from bronchitis where such interventions yield no benefit. Similarly, postnasal drip, stemming from or , presents with throat clearing and nasal symptoms, alleviating with antihistamines or nasal corticosteroids, unlike the lower airway in bronchitis unresponsive to these treatments. In smokers with persistent cough, must be ruled out, as chronic bronchitis symptoms can mask early malignancy. Key differentiators include unexplained , , or digital clubbing, which are uncommon in isolated chronic bronchitis; computed tomography (CT) scans may detect masses or nodules warranting , particularly in high-risk individuals. Persistent symptoms beyond typical bronchitis duration, especially without infection resolution, necessitate further evaluation to exclude neoplastic causes.

History

Early Descriptions

The earliest recognitions of conditions akin to bronchitis date back to , where around 400 BCE described "catarrhal" coughs involving excessive mucus secretions in the upper airways, a hallmark feature of what would later be termed bronchitis. These observations framed respiratory ailments as imbalances of bodily humors, with viewed as a downward flow of leading to inflammation and productive cough. In the late , English physician John Floyer provided one of the first detailed accounts of chronic respiratory symptoms in his 1698 treatise A Treatise of the Asthma, where he documented persistent coughs and wheezing episodes, attributing them to spasms and mucus accumulation in the bronchi—symptoms overlapping with chronic bronchitis—based partly on his own experience with bronchial . Building on earlier work by , Floyer described such conditions as "bastard peripneumonia," distinguishing them from acute pneumonias but still linking them to humoral imbalances and environmental triggers like cold air. The term "bronchitis" was formally coined in 1808 by British physician Charles Badham, who defined it as an inflammatory affection of the lining the bronchial tubes, often presenting as a chronic with cough and expectoration. This conceptualization emphasized its inflammatory nature without clear separation from other pulmonary disorders. In 1819, René Laënnec advanced the understanding through his invention of the and publication of Traité de l'Auscultation Médiate, where he auscultated characteristic bronchial rales and wheezes, enabling more precise identification of bronchitis as distinct from pneumonias, though early views often conflated it with the initial stages of phthisis () due to shared symptoms of and production. Initially, bronchitis was regarded primarily as a benign, recurrent catarrhal exacerbated by and occupation, rather than a specific entity.

Modern Understanding and Advances

In the mid-20th century, chronic bronchitis gained recognition as a key component of (COPD), particularly through the British hypothesis proposed in 1953, which linked repeated chest infections and to its . This perspective shifted understanding from isolated bronchitis to a broader obstructive disorder, with early epidemiological evidence emerging in the 1950s associating with and production characteristic of bronchitis. Pioneering work by and Austin Bradford Hill in the 1950s, initially focused on , extended to respiratory conditions, influencing the 1964 U.S. Surgeon General's report that affirmed smoking as a cause of chronic bronchitis and premature mortality. By the 1960s, diagnostic criteria for COPD, including chronic bronchitis, were formalized, beginning with the 1959 CIBA Guest Symposium and solidified by the American Thoracic Society's 1962 standards, which emphasized to confirm airflow obstruction. These criteria marked a transition to evidence-based , distinguishing COPD from other respiratory ailments and integrating bronchitis as a involving hypersecretion. Concurrently, research in the 1970s elucidated the viral etiology of , identifying respiratory viruses such as , parainfluenza, and as primary causes in the majority of cases, often through early virological studies that highlighted seasonal patterns and reduced the emphasis on bacterial origins. Advances in the introduced targeted therapies for specific bronchitis variants, notably biologics like and reslizumab, which inhibit interleukin-5 to address in , demonstrating efficacy in reducing and symptoms. These monoclonal antibodies, approved for severe , have been adapted off-label for non-asthmatic based on biomarker-guided selection. Recent developments in research have further refined understanding, revealing in the —such as reduced bacterial diversity and overgrowth of pathogens like in chronic bronchitis—as a contributor to and exacerbations, opening avenues for microbiota-modulating interventions. Personalized medicine approaches for bronchitis variants have gained traction, leveraging biomarkers like sputum eosinophils for eosinophilic subtypes or genetic profiling for protracted bacterial bronchitis, to tailor therapies such as antibiotics or biologics, improving outcomes in heterogeneous COPD presentations. This shift emphasizes endotyping based on microbial composition and inflammatory profiles, with ongoing studies exploring fecal transplantation and precision antibiotics to address variant-specific .

References

  1. https://www.mayoclinic.org/diseases-conditions/bronchitis/symptoms-causes/syc-20355566
  2. https://www.nhlbi.nih.gov/health/bronchitis
  3. https://www.cdc.gov/acute-bronchitis/about/index.html
  4. https://www.ncbi.nlm.nih.gov/books/NBK556044/
  5. https://www.ncbi.nlm.nih.gov/books/NBK537353/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7120972/
  7. https://www.ncbi.nlm.nih.gov/books/NBK470240/
  8. https://www.ncbi.nlm.nih.gov/books/NBK448067/
  9. https://www.inogen.com/blog/acute-vs-chronic-bronchitis-understanding-differences/
  10. https://www.ncbi.nlm.nih.gov/books/NBK482437/
  11. https://www.lung.org/lung-health-diseases/lung-disease-lookup/chronic-bronchitis
  12. https://www.nlm.nih.gov/medlineplus/ency/article/001087.htm
  13. https://my.clevelandclinic.org/health/diseases/17727-hypoxemia
  14. https://www.mayoclinic.org/diseases-conditions/chronic-cough/symptoms-causes/syc-20351575
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7129975/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC7151913/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3157944/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4373868/
  19. https://www.aafp.org/pubs/afp/issues/2010/1201/p1345.html
  20. https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON550
  21. https://www.cdc.gov/respiratory-viruses/data/index.html
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5598418/
  23. https://www.nhlbi.nih.gov/health/alpha-1-antitrypsin-deficiency
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC59565/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4951627/
  26. https://goldcopd.org/2024-gold-report/
  27. https://goldcopd.org/spirometry-quick-guide/
  28. https://radiopaedia.org/articles/chronic-obstructive-pulmonary-disease-1?lang=us
  29. https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/symptoms-diagnosis/diagnosing
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3998207/
  31. https://emedicine.medscape.com/article/297664-differential
  32. https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf
  33. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-class-medication-copd
  34. https://pubmed.ncbi.nlm.nih.gov/38767614/
  35. https://us.gsk.com/en-us/media/press-releases/nucala-mepolizumab-approved-by-us-fda-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-copd/
  36. https://medlineplus.gov/chronicbronchitis.html
  37. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
  38. https://www.cdc.gov/tobacco/campaign/tips/diseases/copd.html
  39. https://www.cdc.gov/copd/about/index.html
  40. https://www.mayoclinic.org/diseases-conditions/chronic-bronchitis/symptoms-causes/syc-20355570
  41. https://www.cdc.gov/vaccines-adults/recommended-vaccines/index.html
  42. https://www.nature.com/articles/s41533-021-00226-y
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10642213/
  44. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812622
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4531654/
  46. https://pubmed.ncbi.nlm.nih.gov/38113129/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC5783052/
  48. https://journal.chestnet.org/article/S0012-3692%2815%2952839-0/fulltext
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC7426454/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC7167774/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC5772114/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC4608206/
  53. https://www.ahajournals.org/doi/10.1161/jaha.114.000865
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC10928548/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10857890/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3236535/
  57. https://www.mayoclinic.org/diseases-conditions/copd/symptoms-causes/syc-20353679
  58. https://my.clevelandclinic.org/health/diseases/8709-chronic-obstructive-pulmonary-disease-copd
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6596437/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3282601/
  61. https://my.clevelandclinic.org/health/diseases/3993-bronchitis
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC3332192/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC7883910/
  64. https://litfl.com/john-floyer/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC1570491/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC2706597/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC9682580/
  68. https://www.news-medical.net/health/History-of-Chronic-Obstructive-Pulmonary-Disease.aspx
  69. https://www.tandfonline.com/doi/full/10.3109/15412555.2015.1043521
  70. https://www.acpjournals.org/doi/10.7326/0003-4819-133-12-200012190-00014
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9356173/
  72. https://esmed.org/MRA/mra/article/view/5052
  73. https://www.nature.com/articles/s41392-023-01722-y
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC6636434/
  75. https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-025-03356-w
Add your contribution
Related Hubs
User Avatar
No comments yet.